CIBC Private Wealth Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

CIBC Private Wealth Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-29,496	Closed	-$2.94M	–	1079
2021 Q1	$2.94M	Buy	29,496 +333	+1%	+$38.8K	0.01%	475
2020 Q4	$3.6M	Buy	29,163 +14,664	+101%	+$1.93M	0.01%	420
2020 Q3	$1.41M	Buy	+14,499	New	+$1.81M	﹤0.01%	504
2018 Q2	–	Sell	-12,591	Closed	-$258K	–	2131
2018 Q1	$258K	Hold	12,591	–	–	﹤0.01%	895
2017 Q4	$357K	Hold	12,591	–	–	﹤0.01%	842
2017 Q3	$392K	Hold	12,591	–	–	﹤0.01%	807
2017 Q2	$398K	Hold	12,591	–	–	﹤0.01%	554
2017 Q1	$285K	Buy	+12,591	New	+$311K	﹤0.01%	563

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CIBC Private Wealth Group's RETA Position: Q2 2021 in Review

CIBC Private Wealth Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2021, closing a stake of 29,496 shares — an estimated $2.94M sold.

CIBC Private Wealth Group first reported a position in RETA in Q1 2017 and held it in 8 quarters. The position peaked at $3.6M in Q4 2020. 194 funds tracked by Wall St. Rank hold RETA as of Q2 2021.

CIBC Private Wealth Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2021 after selling out during the quarter.
CIBC Private Wealth Group sold 29,496 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2021, an estimated $2.94M.
CIBC Private Wealth Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2017 and held it in 8 quarters.
CIBC Private Wealth Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.6M in Q4 2020.
194 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2021.

Based on CIBC Private Wealth Group's 13F filing for Q2 2021, filed 16 Aug 2021.